FDA VRBPAC Meeting Today to Discuss the Pfizer-BioNTech COVID-19 Vaccine in 5 to 11 Year Olds

The committee is meeting today to review the data presented to them, and will vote to either recommend or not an Emergency Use Authorization in this pediatric population.

The Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) panel is meeting today to discuss whether or not to recommend an Emergency Use Authorization (EUA) for the Pfizer-BioNTech vaccine in the 5 to 11 year old pediatric population.

The meeting will include a presentation by Pfizer who will be discussing data on their COVID-19 vaccine series in this age group.

The Centers for Disease Control and Prevention (CDC) will be presenting on the epidemiology of COVID-19 in children, followed by the known safety signals of vaccines in adolescents and young adults.

The FDA will review the Pfizer-BioNTech vaccine submission and present post-authorization evaluation and a benefit-risk analysis.

There will be a public comment portion of the meeting and a question and answer session for the committee in the afternoon.

After this, the committee will take a vote on whether or not to recommend the EUA. Check back later today when the committee votes.